寡转移性疾病的特征描述与分类:ESTRO与EORTC共识推荐
欧洲放射肿瘤学会(ESTRO)与欧洲癌症研究与治疗组织(EORTC)召集20位国际专家,通过系统文献综述和德尔菲共识流程,建立了寡转移性疾病的综合特征描述与分类系统。共识确定17项特征因子,并以既往广泛转移病史区分诱导性寡转移与真性寡转移,真性寡转移再分为重复性、新发(同步/异时)、寡复发、寡进展和寡持续。该分类与命名有待OligoCare研究前瞻性验证。
要点
- 寡转移性疾病定义为介于局限期与广泛转移之间的中间状态,诊断仅基于影像学发现。
- 所有接受根治性局部治疗的寡转移患者应评估17项特征因子,无论是否在临床试验中。
- 既往广泛转移病史区分诱导性寡转移与真性寡转移,真性寡转移再按病史与时机细分。
核心结论
- 建立寡转移性疾病的总体 umbrella 术语及多层次分类命名系统。
- 以既往广泛转移病史区分诱导性寡转移与真性寡转移。
- 真性寡转移细分为重复性寡转移与新发寡转移(同步/异时)。
- 进一步按诊断时机和病灶进展状态分为寡复发、寡进展和寡持续。
研究设计与样本
- 20位国际专家(含19位ESTRO/EORTC OligoCare项目成员)参与的共识制定。
- 先进行系统文献综述,识别前瞻性干预性寡转移临床试验的纳入与排除标准。
- 采用德尔菲共识流程筛选出17项寡转移特征因子。
- 第二轮德尔菲法建立分类决策树与命名。
主要发现
- 早期临床研究显示,在标准系统治疗基础上加根治性局部治疗可改善寡转移患者生存。
- 影像学上少量转移灶可代表不同临床场景,预后与治疗策略可能不同。
- 尚无临床可用的生物标志物识别真性寡转移,诊断仅基于影像学。
- 共识确定17项特征因子应在所有接受根治性局部治疗的寡转移患者中评估。
关键数值与推荐
- 既往广泛转移病史:有则归类为诱导性寡转移,无则归类为真性寡转移。
- 真性寡转移中,既往寡转移病史区分重复性寡转移(有)与新发寡转移(无)。
- 新发寡转移按诊断时机分为同步与异时。
- 按诊断于无治疗间期或系统治疗期间、以及病灶是否进展,分为寡复发、寡进展和寡持续。
- 17项特征因子应在所有接受根治性局部治疗的寡转移患者中评估,无论是否在临床试验中。
临床怎么用
- 临床评估寡转移患者时,应系统采集17项特征因子以指导分层。
- 根据既往广泛转移病史区分诱导性与真性寡转移,辅助治疗决策。
- 真性寡转移进一步按病史、时机和病灶进展状态细分,以匹配不同治疗策略。
- 该分类命名需在OligoCare研究中进行前瞻性验证。
局限性
- 缺乏随机3期试验证据,早期临床研究显示生存改善但需进一步验证。
- 无临床可用的生物标志物识别真性寡转移,诊断仅依赖影像学。
- 分类与命名系统有待OligoCare研究前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when radical local therapy is added to standard systemic therapy for oligometastatic disease. However, since no biomarker for the identification of patients with true oligometastatic disease is clinically available, the diagnosis of oligometastatic disease is based solely on imaging findings. A small number of metastases on imaging could represent different clinical scenarios, which are associated with different prognoses and might require different treatment strategies. 20 international experts including 19 members of the European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer OligoCare project developed a comprehensive system for characterisation and classification of oligometastatic disease. We first did a systematic review of the literature to identify inclusion and exclusion criteria of prospective interventional oligometastatic disease clinical trials. Next, we used a Delphi consensus process to select a total of 17 oligometastatic disease characterisation factors that should be assessed in all patients treated with radical local therapy for oligometastatic disease, both within and outside of clinical trials. Using a second round of the Delphi method, we established a decision tree for oligometastatic disease classification together with a nomenclature. We agreed oligometastatic disease as the overall umbrella term. A history of polymetastatic disease before diagnosis of oligometastatic disease was used as the criterion to differentiate between induced oligometastatic disease (previous history of polymetastatic disease) and genuine oligometastatic disease (no history of polymetastatic disease). We further subclassified genuine oligometastatic disease into repeat oligometastatic disease (previous history of oligometastatic disease) and de-novo oligometastatic disease (first time diagnosis of oligometastatic disease). In de-novo oligometastatic disease, we differentiated between synchronous and metachronous oligometastatic disease. We did a final subclassification into oligorecurrence, oligoprogression, and oligopersistence, considering whether oligometastatic disease is diagnosed during a treatment-free interval or during active systemic therapy and whether or not an oligometastatic lesion is progressing on current imaging. This oligometastatic disease classification and nomenclature needs to be prospectively evaluated by the OligoCare study.
引用
- Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020. PMID: 31908301. doi:10.1016/S1470-2045(19)30718-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。